Anti-Inhibitor Coagulant Complex- @- Antihemophilic Agents
Drug Name:
Anti-Inhibitor Coagulant Complex- @- Antihemophilic Agents
List Of Brands:
Indication Type Description:
Adverse Reaction:
Allergic - allergic reactions ranging from mild to short-term urticarial rashes to severe anaphylactoid
reactions. discontinue immediately if such signs appear.
Cardiovascular- thromboembolic reactions may occur particularly after high doses or in patients
with thrombotic risk factors.
Contra-Indications:
Special Precautions-
Potential disease transmission- AICC is made from human plasma . Products made from plasma
may contain infectious agents such as viruses, that can cause disease. The risk can be reduced by
effetive screening of the donor , testing for infectious agents
Idenification of clotting deficiency- use AICC only in patients with circulating inhibitors to one or more
coagulation factors and do not use it for the treatment of bleeding episodes resulting from coagulation
factor deficiency. Do not give it to patients with significant signs of disseminated intravascular
coagulation DIC or fibronolysis
High doses - give high doses of AICC only as long as absolutely necessary to stop bleeding
Concomittant antifibrinolytics- it has been reported that AICC and antifibronolytics have been given
simultaneously without complications. It is however, recommended not to use antifibrinolysis until
12 hours after the administration of AICC.
Anamnestic response- anamnestic responses with rises in factor VIII inhibitor titer have been
observed in 20% of the cases.
Viral infections- individuals who receive infusions of blood or plasma products may develop
signs and/or symptoms of some viral infections, paricularly non-A , non-B hepatitis
Pregnancy- not known whether AICC can cause fetal harm when administered to a pregnant woman.
Give to a pregnant woman only if required
Children- no data are available regarding use of AICC in children
Monitoring- monitor patients receiving AICC 100units/kg of body weight for the development of
DIC and/or symptoms of acute coronary ischemia.
Dosages/ Overdosage Etc:
Indication-
Hemorrhage
Dosage-
Recommended dosage- as general gideline a dosage range of 50 to 100 units of AICC per kg of body
weight is recommended.
Patient Information:
1. Some viruses such as paraviris B19 or hepatitis A are particularly difficult to remove or
inactivate at this time.
2. Paravirus B19 most seriously affect pregnant woman or immune-compromised individuals
3. Symptoms of paravirus B19 include fever, drowsiness, chills, and runny nose followed by
2 weeks later by a rash and joint pain.
4. Evidence of hepatitis A several days or weeks of poor appetite, tiredness, and low grade
fever, followed by nausea, vomiting, and pain in the belly. Dark urine and yellow complexion
are also common symptoms.
5. Encourage patients to consult their health care provider if such symptoms develop.
Pregnancy and lactation:
Pregnancy-
Not known whether AICC can cause fetal harm when administered to a pregnant woman.
Give to a pregnant woman only if required
Children-
No data are available regarding use of AICC in children